These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26816538)

  • 1. Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non-small cell lung cancer.
    Miao J; Zhang W; Hu X; Chen S; Hu B; Li H
    Thorac Cancer; 2016 Jan; 7(1):44-9. PubMed ID: 26816538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.
    Shen WY; Ji J; Zuo YS; Pu J; Xu YM; Zong CD; Tao GZ; Chen XF; Ji FZ; Zhou XL; Han JH; Wang CS; Yi JG; Su XL; Zhu WG
    Radiother Oncol; 2014 Jan; 110(1):120-5. PubMed ID: 24183868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC].
    Peng S; Li X; Wang Y; Liu J
    Zhongguo Fei Ai Za Zhi; 2017 Jul; 20(7):485-489. PubMed ID: 28738965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.
    Zhang L; Ou W; Liu Q; Li N; Liu L; Wang S
    Thorac Cancer; 2014 Jan; 5(1):50-6. PubMed ID: 26766972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The study of peri-operative chemotherapy in stage I-IIIa NSCLC].
    Liao ML; Zhou YZ; Ding JA; Ni GX; Zhao JM; Chen WH; Han BH; Shen J; Bai H; Chen ZW; Ji H; Wang HM; Zhou Z
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):962-6. PubMed ID: 12899797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Video-assisted thoracoscopic lobectomy mitigates adverse oncological effects of delayed adjuvant chemotherapy for nonsmall cell lung cancer patients.
    Jing X; Lin Y; Zhang B; Zhang G
    J BUON; 2016; 21(6):1524-1529. PubMed ID: 28039718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center.
    Zhu Y; Zhai X; Chen S; Wang Z
    Thorac Cancer; 2016 Jul; 7(4):399-405. PubMed ID: 27385981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- apy: a Clinical Study].
    Hou WX; Li HG; Chen ZW; Zhu LH; Zhao LH; Tian JH; Xu WJ; Zhou L; Yao YL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jun; 35(6):648-53. PubMed ID: 26242112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and Potential Application of Neoadjuvant Chemotherapy in Patients with IIIa Stage Non-small Cell Lung Cancer].
    Tang C; Qin S; Wu W; Wu Y; Zhang T
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):100-106. PubMed ID: 28228221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
    Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
    Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
    Yokomise H; Liu D; Ishikawa S; Go T; Gotoh M; Okuda M; Tarumi S; Kasai Y; Matsuura N
    Anticancer Res; 2013 Dec; 33(12):5597-602. PubMed ID: 24324104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects.
    Zhao X; Su Y; You J; Gong L; Zhang Z; Wang M; Zhao Z; Zhang Z; Li X; Wang C
    Oncotarget; 2016 Sep; 7(38):62619-62626. PubMed ID: 27566586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
    Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
    Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.